Home › Research › Lewy body dementia
Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia
Pelin Sordu, Merve Alaylıoğlu, Bedia Samancı, Ersel Bulu, Zeynep Ece Kaya Güleç, Başar Bılgıç, Hasmet Ayhan Hanagasi, Hakan I. Gurvit et al.. Journal of Alzheimer s Disease, 2025-03-21
Topic: Brain proteins, microglia and lab models
Plain-language summary
Background The data that we gathered from a protein-protein interaction (PPI) prediction tool, FpClass, and a limited number of studies indicated that the chaperones HSP90AA1, HSPA4, STUB1/CHIP might interact with amyloid-β (Aβ) and/or tau and could subsequently be co-released into the cerebrospinal fluid (CSF). Therefore, we investigated CSF levels of HSP90AA1, HSPA4, and STUB1/CHIP in Alzheimer's disease (AD), Non-AD mild cognitive impairment (Non-AD MCI), and frontotemporal dementia (FTD) cases. Methods The CSF levels of HSP90AA1, HSPA4, STUB/CHIP, and core AD biomarkers were determined by ELISA in AD (n = 90), Non-AD MCI (n = 27), FTD (n = 15), and subjective cognitive impairment (SCI) (n = 20) subjects. Results HSP90AA1 levels were significantly higher in AD cases compared to the SCI subjects. The CSF levels of STUB1/CHIP were significantly lower in AD, Non-AD MCI and FTD cases compared to the SCI subjects. STUB1/CHIP levels of FTD cases were significantly lower than all other groups. HSPA4 levels was correlated with core AD biomarkers (Aβ 1–42, p-Tau, t-Tau) regardless of disease. Non- APOE ε4 carrier FTD cases also had significantly lower STUB1/CHIP levels than other groups. Conclusions The STUB1/CHIP holds promise as a potential biomarker for distinguishing between SCI subjects, AD, and FTD. Furthermore, APOE might serve as an additional discriminatory factor that might be integrated with this chaperone for enhanced discrimination.
What this study adds
Evidence grade: Low
The record lists 90 participants. This study found that cerebrospinal fluid levels of STUB1/CHIP were significantly lower in Alzheimer's disease, non-AD mild cognitive impairment, and frontotemporal dementia compared to subjective cognitive impairment, and HSP90AA1 was higher in AD. It suggests STUB1/CHIP holds promise as a potential biomarker for distinguishing between these conditions, but no treatment or cure is offered.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sordu, P., Alaylıoğlu, M., Samancı, B., Bulu, E., Güleç, Z. E. K., Bılgıç, B., et al. (2025). Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia. Journal of Alzheimer s Disease. https://doi.org/10.1177/13872877251329540
Vancouver
Sordu P, Alaylıoğlu M, Samancı B, Bulu E, Güleç ZEK, Bılgıç B, et al. Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia. Journal of Alzheimer s Disease. 2025. doi:10.1177/13872877251329540. PMID: 40116694.
BibTeX
@article{sordu2025-40116694,
author = {Sordu, Pelin and Alaylıoğlu, Merve and Samancı, Bedia and Bulu, Ersel and Güleç, Zeynep Ece Kaya and Bılgıç, Başar and Hanagasi, Hasmet Ayhan and Gurvit, Hakan I. and others},
title = {{Cerebrospinal fluid HSP90AA1, HSPA4, and STUB1/CHIP levels in Alzheimer's disease, mild cognitive impairment, and frontotemporal dementia}},
journal = {Journal of Alzheimer s Disease},
year = {2025},
doi = {10.1177/13872877251329540},
pmid = {40116694},
url = {https://doi.org/10.1177/13872877251329540}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Background The data that we gathered from a protein-protein interaction (PPI) prediction tool, FpClass, and a limited number of studies indicated that the chaperones HSP90AA1, HSPA4, STUB1/CHIP might interact with amyloid-β (Aβ) and/or tau and could subsequently be co-released into the cerebrospinal fluid (CSF).
- Results HSP90AA1 levels were significantly higher in AD cases compared to the SCI subjects.
- The CSF levels of STUB1/CHIP were significantly lower in AD, Non-AD MCI and FTD cases compared to the SCI subjects.
- STUB1/CHIP levels of FTD cases were significantly lower than all other groups.
- Non- APOE ε4 carrier FTD cases also had significantly lower STUB1/CHIP levels than other groups.
Why it matters
This study found that cerebrospinal fluid levels of STUB1/CHIP were significantly lower in Alzheimer's disease, non-AD mild cognitive impairment, and frontotemporal dementia compared to subjective cognitive impairment, and HSP90AA1 was higher in AD. It suggests STUB1/CHIP holds promise as a potential biomarker for distinguishing between these conditions, but no treatment or cure is offered.
Study details
- Participants90
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 90 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Duygu Gezen‐Ak: h-index 25 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Istanbul University: institution h-index 441 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40116694) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Lewy body dementia from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.